Dendrimers for gene delivery - A potential approach for ocular therapy?

Journal of Pharmacy and Pharmacology

Volumn 66, Issue 4, 2014, Pages 542-556

  Chaplot, Sahil P ^a   Rupenthal, Ilva D ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

dendrimers; gene therapy; non viral vectors; ocular diseases

Indexed keywords

DENDRIMERS; GENE THERAPY; NON-VIRAL VECTORS; OCULAR DISEASES;

ANIMALS; DENDRIMERS; DRUG DELIVERY SYSTEMS; EYE; EYE DISEASES; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS;

EID: 84899085765     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12104     Document Type: Review

References (118)

1. Buhleier E, etal. 'Cascade'- and 'Nonskid-Chain-like' syntheses of molecular cavity topologies. Synthesis 1978; 2: 155-158.
2. Denkewalter RG, etal. Macromolecular highly branched homogeneous compound based on lysine units. US Patent 4,289,872 1981.
3. Newkome GR, etal. Micelles. Part 1. Cascade molecules: a new approach to micelles. A [27]-arborol. J Org Chem 1985; 50: 2003-2004.
4. Tomalia DA, Dewald JR,. Dense star polymers having core, core branches, terminal groups. US Patent 4,507,466 1985.
5. Tomalia DA,. Birth of a new macromolecular architecture: dendrimers as quantized building blocks for nanoscale synthetic organic chemistry. Aldrichim Acta 2004; 37: 39-57.
6. Dutta T, etal. Dendrimer nanocarriers as versatile vectors in gene delivery. Nanomed-Nanotechnol 2010; 6: 25-34.
7. Liu M, Fréchet JMJ,. Designing dendrimers for drug delivery. Pharm Sci Technolo Today 1999; 2: 393-401.
8. Tomalia DA,. Birth of a new macromolecular architecture: dendrimers as quantized building blocks for nanoscale synthetic polymer chemistry. Prog Polym Sci 2005; 30: 294-324.
9. Nanjwade BK, etal. Dendrimers: emerging polymers for drug-delivery systems. Eur J Pharm Sci 2009; 38: 185-196.
10. Coles DJ, Toth I,. Dendritic peptide-based carriers for gene delivery. Curr Drug Deliv 2009; 6: 338-342.
11. Liu X, etal. Dendrimers as non-viral vectors for siRNA delivery. New J Chem 2012; 36: 256-263.
12. Svenson S, Tomalia DA,. Dendrimers in biomedical applications-reflections on the field. Adv Drug Deliv Rev 2005; 57: 2106-2129.
13. Mignani S, etal. Expand classical drug administration ways by emerging routes using dendrimer drug delivery systems: a concise overview. Adv Drug Deliv Rev 2013; 65: 1316-1330.
14. Biswas S, Torchilin VP,. Dendrimers for siRNA delivery. Pharmaceuticals 2013; 6: 161-183.
15. Tomalia DA,. Starburst dendrimers-nanoscopic macromolecules according to dendritic rules and principles. Macromol Symp 1996; 101: 243-255.
16. Hawker CJ, Fréchet JMJ,. Preparation of polymers with controlled molecular architecture. A new convergent approach to dendritic macromolecules. J Am Chem Soc 1990; 112: 7638-7647.
17. Singh P,. Dendrimers and their applications in immunoassays and clinical diagnostics. Biotechnol Appl Biochem 2007; 48: 1-9.
18. Matthews OA, etal. Dendrimers-branching out from curiosities into new technologies. Prog Polym Sci 1998; 23: 1-56.
19. Fréchet JMJ, Tomalia DA,. Dendrimers and Other Dendritic Polymers. Chichester, NY: John Wiley & Sons, Ltd, 2001.
20. Maraval V, etal. 'Lego' chemistry for the straightforward synthesis of dendrimers. J Org Chem 2003; 68: 6043-6046.
21. Wu P, etal. Efficiency and fidelity in a click-chemistry route to triazole dendrimers by the copper(i)-catalyzed ligation of azides and alkynes. Angew Chem Int Ed Engl 2004; 43: 3928-3932.
22. Briand P, Kahn A,. [Values and limits of adenoviral vectors for gene transfer in vivo]. Pathol Biol (Paris) 1993; 41: 663-671 [in German].
23. Shcharbin DG, etal. Dendrimers in gene transfection. Biochemistry (Moscow) 2009; 74: 1070-1079.
24. Bochot A, Fattal E,. Liposomes for intravitreal drug delivery: a state of the art. J Control Release 2012; 161: 628-634.
25. Fattal E, Bochot A,. Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA. Adv Drug Deliv Rev 2006; 58: 1203-1223.
26. Vigderman L, Zubarev ER,. Therapeutic platforms based on gold nanoparticles and their covalent conjugates with drug molecules. Adv Drug Deliv Rev 2013; 65: 663-676.
27. Slowing II, etal. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev 2008; 60: 1278-1288.
28. Hoyer J, Neundorf I,. Peptide vectors for the nonviral delivery of nucleic acids. Accounts Chem Res 2012; 45: 1048-1056.
29. Shim MS, Kwon YJ,. Stimuli-responsive polymers and nanomaterials for gene delivery and imaging applications. Adv Drug Deliv Rev 2012; 64: 1046-1059.
30. Panyam J, Labhasetwar V,. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003; 55: 329-347.
31. Patri AK, Simanek E,. Biological applications of dendrimers. Mol Pharm 2012; 9: 341-341.
32. Gajbhiye V, etal. Dendrimers as therapeutic agents: a systematic review. J Pharm Pharmacol 2009; 61: 989-1003.
33. Kambhampati SP, Kannan RM,. Dendrimer nanoparticles for ocular drug delivery. J Ocul Pharmacol Ther 2013; 29: 151-165.
34. Dufes C, etal. Dendrimers in gene delivery. Adv Drug Deliv Rev 2005; 57: 2177-2202.
35. Jain K, etal. Dendrimer toxicity: let's meet the challenge. Int J Pharm 2010; 394: 122-142.
36. Duncan R, Izzo L,. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev 2005; 57: 2215-2237.
37. Parekh HS,. The advance of dendrimers-a versatile targeting platform for gene/drug delivery. Curr Pharm Des 2007; 13: 2837-2850.
38. Eliyahu H, etal. Polymers for DNA delivery. Molecules 2005; 10: 34-64.
39. Fischer D, etal. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 2003; 24: 1121-1131.
40. Lee CC, etal. Designing dendrimers for biological applications. Nat Biotech 2005; 23: 1517-1526.
41. Vandamme TF, Brobeck L,. Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release 2005; 102: 23-38.
42. Nam HY, etal. Evaluation of generations 2, 3 and 4 arginine modified PAMAM dendrimers for gene delivery. Int J Pharm 2008; 363: 199-205.
43. Singh P, etal. Folate and folate-PEG-PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice. Bioconjug Chem 2008; 19: 2239-2252.
44. Arima H, etal. Enhancement of gene expression by polyamidoamine dendrimer conjugates with alpha-, beta-, and gamma-cyclodextrins. Bioconjug Chem 2001; 12: 476-484.
45. Cloninger MJ,. Biological applications of dendrimers. Curr Opin Chem Biol 2002; 6: 742-748.
46. Sadler K, Tam JP,. Peptide dendrimers: applications and synthesis. J Biotechnol 2002; 90: 195-229.
47. Crespo L, etal. Peptide and amide bond-containing dendrimers. Chem Rev 2005; 105: 1663-1682.
48. Bruckdorfer T, etal. From production of peptides in milligram amounts for research to multi-tons quantities for drugs of the future. Curr Pharm Biotechnol 2004; 5: 29-43.
49. Kiselev AV, etal. Lysine dendrimers as vectors for delivering genetic constructs to eukaryotic cells. Genetika 2007; 43: 725-733.
50. Boyd BJ, etal. Cationic poly-L-lysine dendrimers: pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats. Mol Pharm 2006; 3: 614-627.
51. Bikram M, etal. Biodegradable poly(ethylene glycol)-co-poly(L-lysine)-g- histidine multiblock copolymers for nonviral gene delivery. Macromolecules 2004; 37: 1903-1916.
52. Yang S, etal. Cellular uptake of self-assembled cationic peptide-DNA complexes: multifunctional role of the enhancer chloroquine. J Control Release 2009; 135: 159-165.
53. Moscicki AB, etal. Measurement of mucosal biomarkers in a phase 1 trial of intravaginal 3% StarPharma LTD 7013 gel (VivaGel) to assess expanded safety. J Acquir Immune Defic Syndr 2012; 59: 134-140.
54. McCarthy TD, etal. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol Pharm 2005; 2: 312-318.
55. Price CF, etal. SPL7013 Gel (VivaGel(R)) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans. PLoS ONE 2011; 6: e24095.
56. Turnbull WB, Stoddart JF,. Design and synthesis of glycodendrimers. J Biotechnol 2002; 90: 231-255.
57. Wada K, etal. Improvement of gene delivery mediated by mannosylated dendrimer/alpha-cyclodextrin conjugates. J Control Release 2005; 104: 397-413.
58. Nishikawa M, etal. Pharmacokinetics and in vivo gene transfer of plasmid DNA complexed with mannosylated poly(L-lysine) in mice. J Drug Target 2000; 8: 29-38.
59. Arima H, etal. Sugar-appended polyamidoamine dendrimer conjugates with cyclodextrins as cell-specific non-viral vectors. Adv Drug Deliv Rev 2013; 65: 1204-1214.
60. Singha K, etal. Polymers in small-interfering RNA delivery. Nucleic Acid Ther 2011; 21: 133-147.
61. Intra J, Salem AK,. Characterization of the transgene expression generated by branched and linear polyethylenimine-plasmid DNA nanoparticles in vitro and after intraperitoneal injection in vivo. J Control Release 2008; 130: 129-138.
62. Schatzlein AG, etal. Preferential liver gene expression with polypropylenimine dendrimers. J Control Release 2005; 101: 247-258.
63. Taratula O, etal. Poly (propyleneimine) dendrimers as potential siRNA delivery nanocarrier: from structure to function. Int J Nanotechnol 2011; 8: 36-52.
64. Russ V, etal. Oligoethylenimine-grafted polypropylenimine dendrimers as degradable and biocompatible synthetic vectors for gene delivery. J Control Release 2008; 132: 131-140.
65. Tack F, etal. Modified poly(propylene imine) dendrimers as effective transfection agents for catalytic DNA enzymes (DNAzymes). J Drug Target 2006; 14: 69-86.
66. Colella P, etal. Ocular gene therapy: current progress and future prospects. Trends Mol Med 2009; 15: 23-31.
67. El Sanharawi M, etal. Protein delivery for retinal diseases: from basic considerations to clinical applications. Prog Retin Eye Res 2010; 29: 443-465.
68. Naik R, etal. Gene delivery to the retina: focus on non-viral approaches. Drug Discov Today 2009; 14: 306-315.
69. Lipinski DM, etal. Clinical applications of retinal gene therapy. Prog Retin Eye Res 2013; 32: 22-47.
70. Thrimawithana TR, etal. Drug delivery to the posterior segment of the eye. Drug Discov Today 2011; 16: 270-277.
71. Edelhauser HF, etal. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci 2010; 51: 5403-5420.
72. Pitkanen L, etal. Neural retina limits the nonviral gene transfer to retinal pigment epithelium in an in vitro bovine eye model. AAPS J 2004; 6: e25.
73. Ambati J, Adamis AP,. Transscleral drug delivery to the retina and choroid. Prog Retin Eye Res 2002; 21: 145-151.
74. Ambati J, etal. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci 2000; 41: 1181-1185.
75. Patel SR, etal. Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye. Invest Ophthalmol Vis Sci 2012; 53: 4433-4441.
76. Kinnunen K, Yla-Herttuala S,. Gene therapy in age related macular degeneration and hereditary macular disorders. Front Biosci 2012; 4: 2546-2557.
77. Mohan RR, etal. Gene therapy in the Cornea: 2005-present. Prog Retin Eye Res 2012; 31: 43-64.
78. Khar RK, etal. Nano-vectors for the ocular delivery of nucleic acid-based therapeutics. Indian J Pharm Sci 2010; 72: 675-688.
79. Bloquel C, etal. Non-viral ocular gene therapy: potential ocular therapeutic avenues. Adv Drug Deliv Rev 2006; 58: 1224-1242.
80. Peeters L, etal. Challenges in non-viral ocular gene transfer. Biochem Soc Trans 2007; 35 (Pt 1): 47-49.
81. Sanders NN, etal. Wanted and unwanted properties of surface PEGylated nucleic acid nanoparticles in ocular gene transfer. J Control Release 2007; 122: 226-235.
82. Urtti A,. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 2006; 58: 1131-1135.
83. Gomes Dos Santos AL, etal. Sustained release of nanosized complexes of polyethylenimine and anti-TGF-beta 2 oligonucleotide improves the outcome of glaucoma surgery. J Control Release 2006; 112: 369-381.
84. Qazi Y, etal. Nanoparticle-mediated delivery of shRNA.VEGF-A plasmids regresses corneal neovascularization. Invest Ophthalmol Vis Sci 2012; 53: 2837-2844.
85. Mo Y, etal. Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutase gene. Mol Vis 2007; 13: 746-757.
86. Ye H, etal. Cationic nano-copolymers mediated IKKbeta targeting siRNA to modulate wound healing in a monkey model of glaucoma filtration surgery. Mol Vis 2010; 16: 2502-2510.
87. Bejjani RA, etal. Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol Vis 2005; 11: 124-132.
88. Carrasquillo KG, etal. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. Invest Ophthalmol Vis Sci 2003; 44: 290-299.
89. De La Fuente M, etal. Novel hyaluronic acid-chitosan nanoparticles for ocular gene therapy. Invest Ophthalmol Vis Sci 2008; 49: 2016-2024.
90. Hu J, etal. A new tool for the transfection of corneal endothelial cells: calcium phosphate nanoparticles. Acta Biomater 2012; 8: 1156-1163.
91. Mannermaa E, etal. Long-lasting secretion of transgene product from differentiated and filter-grown retinal pigment epithelial cells after nonviral gene transfer. Curr Eye Res 2005; 30: 345-353.
92. Peeters L, etal. Post-pegylated lipoplexes are promising vehicles for gene delivery in RPE cells. J Control Release 2007; 121: 208-217.
93. Kawakami S, etal. In vivo gene transfection via intravitreal injection of cationic liposome/plasmid DNA complexes in rabbits. Int J Pharm 2004; 278: 255-262.
94. Bochot A, etal. Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Invest Ophthalmol Vis Sci 2002; 43: 253-259.
95. Marano RJ, etal. Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide. Exp Eye Res 2004; 79: 525-535.
96. Marano RJ, etal. Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Ther 2005; 12: 1544-1150.
97. Parekh HS, etal. Synthesis of a library of polycationic lipid core dendrimers and their evaluation in the delivery of an oligonucleotide with hVEGF inhibition. Bioorg Med Chem 2006; 14: 4775-4780.
98. Chaum E, etal. Polyplex-mediated gene transfer into human retinal pigment epithelial cells in vitro. J Cell Biochem 1999; 76: 153-160.
99. Hudde T, etal. Activated polyamidoamine dendrimers, a non-viral vector for gene transfer to the corneal endothelium. Gene Ther 1999; 6: 939-943.
100. Mannistö M, etal. Structure-activity relationships of poly(L-lysines): effects of pegylation and molecular shape on physicochemical and biological properties in gene delivery. J Control Release 2002; 83: 169-182.
101. Gomes Dos Santos AL, etal. Oligonucleotide-polyethylenimine complexes targeting retinal cells: structural analysis and application to anti-TGFbeta-2 therapy. Pharm Res 2006; 23: 770-781.
102. Johnson LN, etal. Cell penetrating peptide POD mediates delivery of recombinant proteins to retina, cornea and skin. Vision Res 2010; 50: 686-697.
103. Chen W, Dehazya P,. Gene Therapy for Dry Eye Syndrome. Stony Brook, NY: Clear Solutions Biotech, Inc., 2001.
104. Hagigit T, etal. Ocular antisense oligonucleotide delivery by cationic nanoemulsion for improved treatment of ocular neovascularization: an in-vivo study in rats and mice. J Control Release 2012; 160: 225-231.
105. Jiang M, etal. Cationic core-shell liponanoparticles for ocular gene delivery. Biomaterials 2012; 33: 7621-7630.
106. Bloquel C, etal. Plasmid electrotransfer of eye ciliary muscle: principles and therapeutic efficacy using hTNF-alpha soluble receptor in uveitis. FASEB J 2006; 20: 389-391.
107. Peeters L, etal. Can ultrasound solve the transport barrier of the neural retina? Pharm Res 2008; 25: 2657-2665.
108. Ormonde S, etal. Regulation of connexin43 gap junction protein triggers vascular recovery and healing in human ocular persistent epithelial defect wounds. J Membr Biol 2012; 245: 381-388.
109. Rupenthal ID, etal. Ion-activated in situ gelling systems for antisense oligodeoxynucleotide delivery to the ocular surface. Mol Pharm 2011; 8: 2282-2290.
110. Grupcheva CN, etal. Improved corneal wound healing through modulation of gap junction communication using connexin43-specific antisense oligodeoxynucleotides. Invest Ophthalmol Vis Sci 2012; 53: 1130-1138.
111. Deva NC, etal. Connexin43 modulation inhibits scarring in a rabbit eye glaucoma trabeculectomy model. Inflammation 2012; 35: 1276-1286.
112. Thrimawithana TR, etal. In-vitro and in-vivo evaluation of carrageenan/methylcellulose polymeric systems for transscleral delivery of macromolecules. Eur J Pharm Sci 2011; 44: 399-409.
113. Bhisitkul RB, etal. An antisense oligodeoxynucleotide against vascular endothelial growth factor in a nonhuman primate model of iris neovascularization. Arch Ophthalmol 2005; 123: 214-219.
114. Shaunak S, etal. Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat Biotechnol 2004; 22: 977-984.
115. Iezzi R, etal. Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration. Biomaterials 2012; 33: 979-988.
116. Duan X, Sheardown H,. Dendrimer crosslinked collagen as a corneal tissue engineering scaffold: mechanical properties and corneal epithelial cell interactions. Biomaterials 2006; 27: 4608-4617.
117. Wimmer N, etal. Syntheses of polycationic dendrimers on lipophilic peptide core for complexation and transport of oligonucleotides. Bioorg Med Chem Lett 2002; 12: 2635-2637.
118. Coles DJ, etal. The synthesis and characterisation of a novel dendritic system for gene delivery. Tetrahedron 2007; 63: 12207-12214.